FARN.LSE Faron Pharmaceuticals Oy
- Market cap
- GBX 62.9M
- P/E
- -
- P/B
- 6.63x
- ROE
- -294.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is FARN.LSE undervalued?
Graham numberThe Graham number of Faron Pharmaceuticals Oy cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Faron Pharmaceuticals Oy fundamental analysis
No fundamental analysis for Faron Pharmaceuticals Oy yet.
Faron Pharmaceuticals Oy stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Faron Pharmaceuticals Oy
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidate is Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. It is also developing bexmarilimab for the treatment of hematological and solid tumor cancers; and in combina…
Full company profileFaron Pharmaceuticals Oy financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Faron Pharmaceuticals Oy annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.15M | 1.50K | 19.0K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | 1.15M | 1.50K | 19.0K | - | - | - | - | - | - | -326K | -676K |
| Operating Income | -8.86M | -20.7M | -20.0M | -13.1M | -16.7M | -21.1M | -27.4M | -28.6M | -18.7K | -20.3M | -44.7M |
| EBITDA | -9.63M | -20.6M | -19.9M | -12.9M | -16.4M | -20.8M | -27.1M | -28.2M | 296K | -19.9M | -44.0M |
| Net Income | -9.29M | -21.1M | -20.1M | -13.3M | -16.9M | -21.2M | -28.7M | -30.9M | -25.9K | -27.2M | -34.2M |
| EPS | -0.32 | -0.62 | -0.54 | -0.31 | -0.31 | -0.35 | -0.43 | -0.39 | 0.00 | -0.25 | -0.22 |
| Balance Sheet | |||||||||||
| Total Assets | 17.3M | 14.9M | 8.00M | 10.2M | 8.37M | 13.2M | 11.3M | 10.2M | 12.5M | 17.2M | 36.0M |
| Total Liabilities | 6.40M | 10.1M | 7.63M | 8.60M | 10.2M | 10.3M | 22.7M | 25.4M | 22.3M | 35.7M | 24.4M |
| Shareholders' Equity | 10.9M | 4.74M | 369K | 1.61M | -1.85M | 2.92M | -11.5M | -15.2M | -9.76M | -18.5M | 11.6M |
| Cash & Short-term Investments | 11.5M | 9.31M | 4.07M | 7.06M | 4.11M | 6.85M | 6.99M | 6.88M | 9.50M | 12.3M | 32.2M |
| Total Debt | 2.13M | 2.43M | 2.13M | 2.82M | 3.23M | 3.55M | 13.3M | 13.1M | 12.1M | 24.7M | 17.9M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -8.45M | -18.4M | -20.5K | -11.5M | -17.5M | -22.2M | -23.0M | -23.8M | -23.0M | -24.3M | -50.4M |
| Capital Expenditure | 92.0K | 98.0K | 2.00 | 100K | 142K | 474K | 385K | 123K | 226K | 222K | 0.00 |
| Free Cash Flow | -8.54M | -18.5M | -20.5K | -11.6M | -17.6M | -22.7M | -23.4M | -23.9M | -23.2M | -18.1M | -50.4M |
| Ratios | |||||||||||
| ROE | -85.4% | -444.0% | -5,443.4% | -823.7% | - | -726.3% | - | - | - | - | -294.5% |
| ROA | -53.8% | -141.5% | -251.0% | -129.9% | -202.5% | -160.8% | -254.9% | -302.8% | -0.2% | -158.7% | -95.1% |
| Net Profit Margin | -806.1% | -1,408,695.7% | -105,715.8% | - | - | - | - | - | - | - | - |
| Debt to Equity | 0.20x | 0.51x | 5.78x | 1.75x | - | 1.22x | - | - | - | - | 1.54x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Faron Pharmaceuticals Oy dividends
Faron Pharmaceuticals Oy has not paid dividends in the last 9 fiscal years.
Last stock split: 5000:4999 on Aug 7, 2019.
Who owns Faron Pharmaceuticals Oy
- Insiders 15.89%
- Institutions 20.68%
- Public & others 63.44%
- Shares outstanding 203M
- Free float 137M
Faron Pharmaceuticals Oy company profile
- Company name
- Faron Pharmaceuticals Oy
- Ticker
- FARN.LSE
- ISIN
- FI4000153309
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 36
- Fiscal year end
- December
- Address
- Joukahaisenkatu 6 B, Turku, Finland, 20520
- Phone
- 358 2469 5151
- Website
- faron.com
About Faron Pharmaceuticals Oy
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidate is Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. It is also developing bexmarilimab for the treatment of hematological and solid tumor cancers; and in combination with care therapies, azacitidine, and other hypomethylating agents in relapsed/refractory myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. In addition, the company develops receptors involved in regulation of immune response in organ damage and bone marrow regeneration. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.
Faron Pharmaceuticals Oy management
7- Dr. Juho Markku Jalkanen M.D., MSc, Ph.D.Founder, CEO & Director · born 1978
- Mr. Jurriaan DekkersChief Financial Officer · born 1976
- Mr. Heikki JouttijarviChief Technical Officer
- Dr. Maija Hollmen Ph.D.Chief Scientific Officer
- Mr. Vesa Karvonen L.L.M.General Counsel · born 1972
- Dr. Petri Bono M.D., Ph.D.Chief Medical Officer · born 1970
- Mr. Ralph HughesChief Business Officer